A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of XW10508 Immediate and Modified Release Formulations in Healthy Adults
Latest Information Update: 08 Nov 2022
At a glance
- Drugs XW 10508 (Primary)
- Indications Major depressive disorder; Pain
- Focus Adverse reactions; First in man
- Sponsors XWPharma
- 02 Nov 2022 Status changed from recruiting to completed.
- 08 Sep 2021 According to XWPharma media release, the company started dosing of subjects in this trial; initial results from this study is anticipated in early 2022, which will allow for rapid progression into a Phase 2a test of safety and efficacy in patient cohorts
- 21 Jul 2021 New trial record